南京醫藥(600713.SH)子公司擬投建南京醫藥中央物流中心二期項目
格隆匯3月26日丨南京醫藥(600713.SH)公佈,公司全資子公司南京醫藥康捷物流有限責任公司擬投資建設南京醫藥中央物流中心二期項目。項目總投資約2.03億元,建築面積約28,759平方米。
南京物流中心一期項目位於南京市江北新區醫藥谷內,面積70,000平方米,總投資為2.7億元,建築設計容量150-180億元銷售規模,已於2018年建設完畢正式投入使用。目前因公司南京地區經營業務增長和物流資源整合,目前實際業務量已接近設計指標值,預計2022年將達到設計峯值。
根據中央物流中心土地使用情況,原設計規劃中還有辦公樓和中藥煎制中心功能區佔地約5.8畝的土地還未建設。根據公司發展現狀和申報國家應急物資儲備中心的需要,經研究決定,將原設計未建功能部分變更建設為南京物流中心二期。項目新建兩棟物流中心建築物,一棟五層,一棟六層,另在原有中藥材倉庫擴建一層。
二期項目定位為南京地區醫藥零售及電商、醫療器械、第三終端、第三方醫藥物流、政府應急儲備等物流服務,將建成集物流信息化、自動化、智能化高標準智慧化藥品與醫療器械物流中心,預計支撐南京地區增加約80億元銷售規模,滿足未來4-5年南京地區經營發展需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.